CELLUMED CO.,LTD. Financials Cellumed Co.,Ltd.
Equities
A049180
KR7049180003
Medical Equipment, Supplies & Distribution
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,720 KRW | -0.58% |
|
+3.49% | -20.00% |
| Mar. 21 | Cellumed Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Mar. 07 | Cellumed Co.,Ltd. announced that it has received KRW 10.000000362 billion in funding | CI |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 185,609 | 145,472 | 206,385 | 265,306 | 181,555 | 92,011 |
| Enterprise Value (EV) 1 | 191,143 | 147,499 | 190,106 | 253,584 | 181,739 | 100,849 |
| P/E ratio | -19.5 x | -3.45 x | 1,993 x | 32 x | -31.5 x | -2.45 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 17.1 x | 8.12 x | 2.26 x | 2.66 x | 1.49 x | 0.96 x |
| EV / Revenue | 17.6 x | 8.23 x | 2.08 x | 2.54 x | 1.49 x | 1.06 x |
| EV / EBITDA | -18.9 x | -22.3 x | 52.5 x | 40.9 x | -69.3 x | -4.72 x |
| EV / FCF | 114 x | -70.5 x | -33.6 x | -23.3 x | -9.58 x | -10 x |
| FCF Yield | 0.88% | -1.42% | -2.98% | -4.3% | -10.4% | -9.95% |
| Price to Book | 7.03 x | 28.1 x | 7.34 x | 5.53 x | 3.4 x | 4.1 x |
| Nbr of stocks (in thousands) | 20,419 | 24,326 | 34,512 | 39,598 | 41,404 | 42,796 |
| Reference price 2 | 9,090 | 5,980 | 5,980 | 6,700 | 4,385 | 2,150 |
| Announcement Date | 3/19/19 | 3/19/20 | 3/22/21 | 3/21/22 | 3/22/23 | 3/21/24 |
1KRW in Million2KRW
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 10,843 | 17,921 | 91,517 | 99,918 | 122,085 | 95,553 |
| EBITDA 1 | -10,104 | -6,609 | 3,620 | 6,199 | -2,623 | -21,363 |
| EBIT 1 | -12,447 | -8,647 | 2,378 | 4,747 | -4,546 | -23,878 |
| Operating Margin | -114.8% | -48.25% | 2.6% | 4.75% | -3.72% | -24.99% |
| Earnings before Tax (EBT) 1 | -9,671 | -36,456 | 2,748 | 9,076 | -4,800 | -38,581 |
| Net income 1 | -9,269 | -37,259 | 85.58 | 8,181 | -5,571 | -37,298 |
| Net margin | -85.48% | -207.9% | 0.09% | 8.19% | -4.56% | -39.03% |
| EPS 2 | -467.1 | -1,735 | 3.000 | 209.6 | -139.3 | -876.3 |
| Free Cash Flow 1 | 1,678 | -2,092 | -5,664 | -10,903 | -18,966 | -10,037 |
| FCF margin | 15.48% | -11.67% | -6.19% | -10.91% | -15.53% | -10.5% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 3/19/19 | 3/19/20 | 3/22/21 | 3/21/22 | 3/22/23 | 3/21/24 |
1KRW in Million2KRW
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 5,534 | 2,027 | - | - | 184 | 8,838 |
| Net Cash position 1 | - | - | 16,278 | 11,723 | - | - |
| Leverage (Debt/EBITDA) | -0.5477 x | -0.3066 x | - | - | -0.0703 x | -0.4137 x |
| Free Cash Flow 1 | 1,678 | -2,092 | -5,664 | -10,903 | -18,966 | -10,037 |
| ROE (net income / shareholders' equity) | -33.6% | -188% | 6.37% | 18.7% | -9.95% | -97.1% |
| ROA (Net income/ Total Assets) | -13.6% | -9.44% | 2.19% | 3.56% | -3% | -18.7% |
| Assets 1 | 68,245 | 394,886 | 3,910 | 229,509 | 185,921 | 199,601 |
| Book Value Per Share 2 | 1,292 | 213.0 | 814.0 | 1,212 | 1,292 | 525.0 |
| Cash Flow per Share 2 | 395.0 | 663.0 | 557.0 | 523.0 | 240.0 | 146.0 |
| Capex 1 | 650 | 3,912 | 1,617 | 2,272 | 1,804 | 4,161 |
| Capex / Sales | 5.99% | 21.83% | 1.77% | 2.27% | 1.48% | 4.36% |
| Announcement Date | 3/19/19 | 3/19/20 | 3/22/21 | 3/21/22 | 3/22/23 | 3/21/24 |
1KRW in Million2KRW
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -20.00% | 61.14M | |
| +8.70% | 125B | |
| +6.05% | 8.93B | |
| +23.36% | 7.57B | |
| +32.10% | 5.36B | |
| +8.61% | 3.43B | |
| -9.10% | 2.81B | |
| -2.71% | 2.23B | |
| -0.20% | 2.13B | |
| -20.42% | 1.84B |
- Stock Market
- Equities
- A049180 Stock
- Financials Cellumed Co.,Ltd.